Specialty Pharmacy Times: May/June

From the Chairman
Specialty Pharmacy Becomes Larger Part of Cancer Care Continuum
Welcome to the ninth annual Specialty Pharmacy Times oncology issue, in which we focus on the challenges and progress associated with treating cancer in the specialty space.
Oncology: The Gateway to Success in Specialty Pharmacy
If you want to be a player in specialty pharmacy, oncology is the place to be.
Compliance Corner
How Does a Pharmacy Train Staff to Handle HDs?
USP <800> encompasses training, assessment, and standard operating procedures to ensure personnel are properly prepared.
In Practice
Free Drug Starter Programs Are Not All Alike
Although free drug starter programs are commonplace in the specialty pharmacy space, they vary widely in the marketplace.
Viewpoints: The Last Word
Can Newly Proposed Rebate Rule Help With High Oncology Prescription Drug Costs?
On February 6, 2019, the Department of Health and Human Services (HHS) proposed a rebate rule, Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.
Clinical Insights
Nivestym by Pizer, Inc
On July 20, 2018, Pfizer Inc announced the FDA approval of filgrastim-aafi (Nivestym), a biosimilar to Amgen’s biologic Neupogen (filgrastim).
Multiple Myeloma Practice Pearls: Improving Patient Access to Oral Oncolytics
In a Specialty Pharmacy Times® Practice Pearls video series, expert panelists convened to discuss the challenges and best practices for dispensing multiple myeloma medications.
Specialty Pharmacy Takes Center Stage in Cancer Care
The oncology pharmaceutical market is rapidly growing and changing.
Flipping the Script: The Complexities of the Health Care System and the Importance of Cancer Care Management
All stakeholders in the health care continuum should always remember that there is a person at the end of their businesses who depends on them to survive and have a high quality of life.
Debate Around Drug Cost Must Include Proven Value of Drug Therapies
As we debate who should pay for health care and how, it is critical to make clear what we expect to get for those payments: high-quality, cost-effective care that improves patient outcomes—in other words, value.
The Intersection of Technology and Cancer Care: The Opportunity and Implications for Specialty Pharmacy
Technological advancements empower patients to manage their own health.
Ovarian Cancer: The Silent Killer
Ovarian cancer has been dubbed "the silent killer" because of its overall 5-year survival rate of 47%: By the time a woman receives the diagnosis, the prognosis is unfavorable.
Oncology Service Lines Prepare Pharmacy for Shift in Cancer Care Delivery
What can health systems do to provide a seamless journey during a time of uncertainty?
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.